Sutro Biopharma, Inc. (STRO) Tops Q2 EPS by 9c

Sutro Biopharma, Inc. (NASDAQ: STRO) reported Q2 EPS of ($0.64), $0.09 better than the analyst estimate of ($0.73). Revenue for the quarter came in at $10.4 million versus the consensus estimate of $12.56 million.

For earnings history and earnings-related data on Sutro Biopharma, Inc. (STRO) click here.

You May Also Be Interested In

• Ennis (EBF) Reports In-Line Q1 EPS
• Tutor Perini launches $400M senior notes offering due 2033
• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings